Anzac Animal Health

Anzac Animal Health was a specialized veterinary pharmaceutical company dedicated to developing and commercializing niche therapeutic products for companion animals. The company's primary focus was on endocrinology and cardiology, with a portfolio featuring key treatments such as Zycortal for canine Addison's disease and Thyforon for hypothyroidism. Anzac played a critical role in navigating the regulatory pathway for these products in the United States market. In February 2016, the company was acquired by Dechra Pharmaceuticals for an initial consideration of 10 million plus future royalties. This acquisition allowed Dechra to internalize the marketing and distribution of high-value endocrine products in North America, strengthening its position in the global animal health sector.